Stratec Biomedical AG (ETR:SBS) has earned an average recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is €60.50 ($72.02).

SBS has been the subject of several recent research reports. Kepler Capital Markets set a €70.00 ($83.33) price target on Stratec Biomedical and gave the company a “buy” rating in a report on Friday, October 27th. Warburg Research set a €62.00 ($73.81) price target on Stratec Biomedical and gave the company a “buy” rating in a report on Thursday, October 26th. Berenberg Bank set a €59.00 ($70.24) price target on Stratec Biomedical and gave the company a “neutral” rating in a report on Thursday, December 7th. Deutsche Bank set a €56.00 ($66.67) price target on Stratec Biomedical and gave the company a “neutral” rating in a report on Tuesday, October 24th. Finally, Oddo Bhf set a €58.00 ($69.05) price target on Stratec Biomedical and gave the company a “neutral” rating in a report on Monday, October 23rd.

Shares of Stratec Biomedical (ETR:SBS) opened at €67.26 ($80.07) on Tuesday. Stratec Biomedical has a 12 month low of €42.80 ($50.95) and a 12 month high of €70.33 ($83.73).

TRADEMARK VIOLATION WARNING: “Stratec Biomedical AG (SBS) Given Consensus Recommendation of “Hold” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/12/stratec-biomedical-ag-sbs-given-consensus-recommendation-of-hold-by-brokerages.html.

About Stratec Biomedical

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.